{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:07Z","timestamp":1777934647961,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICI) are novel therapeutic strategies in cancer treatment, promoting anti-tumor response by boosting cytotoxic T lymphocytes. Despite their high effectiveness, they can trigger the activation of diverse autoimmune diseases in genetically predisposed individuals. New-onset autoimmune diabetes mellitus type 1 (T1D) is an extremely unusual side effect, described in less than 1% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>Here we present a 44-year-old male diagnosed with non-surgical hepatocarcinoma, developing programmed death ligand-1 inhibitor-induced autoimmune endocrinopathies, presented as diabetic ketoacidosis and thyroiditis. After two cycles of atezolizumab and bevacizumab, he consulted the emergency department with abdominal pain and diabetes cardinal features (polyuria, polydipsia, vomiting). Blood tests demonstrated hyperglycemia &gt;800\u2005mg\/dL, capillary ketonemia &gt;3\u2005mmol\/L, metabolic acidosis (pH 7.24 with HCO3 14\u2005mEq\/L). Subsequent studies detected a low level of C-peptide, and positive glutamic acid decarboxylase and insulinoma-associated antigen-2 antibodies. Thyroid examination was compatible with thyroiditis, showing a high free thyroxine level (1.91\u2005ng\/dL) with low thyrotropin (TSH) (0.08\u2005mIU\/L) and negative anti-TSH receptor antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>After reaching metabolic stabilization, treatment with Atezolizumab was restarted, with no further complications showing size stability in the computed tomography control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>T1D related to ICI is a rare condition that presents as a life-threatening emergency and should be recognized and treated early. Blood glucose and glycated hemoglobin determinations should be performed at periodic visits for detection. There are genetic factors that predispose susceptible individuals, but there is no evidence of studies to be performed before the onset of ICI or preventive strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231151656","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T01:17:25Z","timestamp":1673572645000},"page":"1268-1270","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Atezolizumab induced new-onset type 1 diabetes mellitus"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-4524","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"de Carlos","sequence":"first","affiliation":[{"name":"Endocrinology Department, Hospital de Zumarraga, Zumarraga, Guipuzcoa, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Zabalza","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garcia","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospital Universitario de Araba, Vitoria, Alava, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Marti","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xabier","family":"Ayarza-Marien","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Yoldi","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"bibr1-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"bibr2-10781552231151656","unstructured":"Administration TUSF and D. TECENTRIQ\u00ae (atezolizumab). Highlights of prescribing information [Internet]. 2021 [cited 2022 Jan 10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s042lbl.pdf."},{"key":"bibr3-10781552231151656","unstructured":"IMbrave150 efficacy results: Key secondary endpoints [Internet. Last access 12\/12\/2022]. Available from: https:\/\/www.tecentriq-hcp.com\/hcc\/efficacy\/key-secondary-endpoints.html"},{"key":"bibr4-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"bibr5-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-018-4427-x"},{"key":"bibr6-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"bibr7-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0480-y"},{"key":"bibr8-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.685"},{"key":"bibr9-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2006.3.169"},{"key":"bibr10-10781552231151656","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr11-10781552231151656","volume":"2016","author":"Aleksova J","year":"2016","journal-title":"BMJ Case Rep"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231151656","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231151656","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231151656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:52Z","timestamp":1777688872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231151656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1177\/10781552231151656"],"URL":"https:\/\/doi.org\/10.1177\/10781552231151656","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}